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Objectives:
 
 The use of statins in primary prevention of
cardiovascular disease is currently under debate. This
study characterizes and identifies predictors of the per-
sistence of use of statins in a clinical cohort of subsi-
dized new users of similar age to the WOSCOPS trial
subjects.
 
Methods:
 
 Medical, pharmaceutical, and demographic
records for the period January 1, 1987 through Decem-
ber 31, 1994 were extracted from the databases of
Québec’s provincial health plan for a 10% random
sample of social assistance recipients. Patients remained
eligible for inclusion if they had received a first dispen-
sation of a statin between January 1, 1987 and July 31,
1994. Persistence was defined as the number of days on
treatment with a statin while continuing to renew dis-
pensations within a defined time limit.
 
Results:
 
 New users of statins included 983 social assistance
recipients who were observed for a total of 2,439,153
person-days. Median persistence on statin treatment was
173 (95% CI 
 

 
 155, 204) days. Only 13% of patients
persisted for 5 years of treatment. A higher index of
chronic morbidity, pre-existing cardiovascular disease,
and previous use of nicotinic acid were predictive of
longer persistence on statin medication. Those patients
whose first statin dispensation was for lovastatin discon-
tinued treatment earlier than those whose first dispensa-
tion was for pravastatin or simvastatin.
 
Conclusions:
 
 New users showed low persistence on statins
in a cohort of socially assisted persons aged 45–64,
in spite of the minimal financial cost of the drug for
such beneficiaries of Québec’s provincial health plan.
 
Keywords:
 
 adherence, compliance, discontinuation, dys-
lipidaemia, HMG-CoA reductase inhibitors, persistence,
primary prevention, secondary prevention.
 
Introduction
 
The use of medications can be an effective way to
reduce the occurrence of adverse clinical outcomes
and the concomitant need for more costly techno-
logic interventions by preventing the development
(primary prevention) or progression (secondary
prevention) of a number of chronic diseases. Lipid
modifying agents have been increasingly prescribed
in recent years to reduce the risk of cardiovascular
disease (CVD). The United Kingdom, for example,
experienced a more than 6-fold increase in the use
of cholesterol lowering drugs between 1986 and
1992, and similarly impressive growth in the use
of these drugs has been seen in other countries [1].
According to a recent Datamonitor report [2], it is
expected that 50% of US residents will suffer from
dyslipidaemia by the year 2002. Since life-long
treatment is generally necessary in persons with
abnormal lipids, the economic consequences of
these trends are of great concern. Such concern is
heightened by the fact that a substantial propor-
tion of patients who are started on lipid modifying
agents stop using them [3–6], thereby eventually
losing any health benefit they might have gained
from them, as well as wasting the money used to
pay for the drugs.
Although it has been argued that statins are
generally well tolerated and are thus associated
with high patient compliance in comparison with
the other classes of medication used for hyperlipi-
demia [7], few published studies have investigated
patient compliance on statins among general clini-
cal populations (Andrade et al. 1995, Simons 1996;
Avorn et al. 1998; Eriksson et al. 1998) [3,4,6,8].
Only two of these, Andrade 1995 and Simons
1996, actually estimated the risk of drug discon-
tinuation according to the duration of therapy us-
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ing survival analysis methods. These studies were
only able to provide rates of persistence (survival
on therapy) up to one year following treatment
initiation, however. Moreover, investigated pre-
dictors of discontinuation were limited to subjec-
tively defined reasons for discontinuation. The ob-
jective of the current investigation is to study, in a
representative sample from a large subsidized pop-
ulation, long-term persistence on statins among
new users of these drugs, and to identify and quan-
tify objective predictors of discontinuation.
 
Patients And Methods
 
Source of Data
 
The Régie de l’Assurance Maladie du Québec
(RAMQ) is the provincial health insurance plan
for the province of Québec; during the study pe-
riod it provided complete drug and medical ser-
vices coverage for persons receiving social assis-
tance (welfare) and all persons over the age of 65.
All claims data are captured by the RAMQ ad-
ministrative database and encoded to preserve pa-
tient and physician anonymity prior to their re-
lease for research purposes. The accuracy and
comprehensiveness of the RAMQ pharmaceutical
data have been validated by Tamblyn et [9].
 
Cohort Definition
 
From the RAMQ database, we retrieved demo-
graphic information and all medical services and
pharmaceutical records pertaining to the study pe-
riod January 1, 1987 through December 31, 1994
for a 10% sample of social assistance beneficia-
ries. Patients remained eligible for inclusion in the
cohort of new statin users if they had received a
first (index) statin dispensation between January
1, 1987 and July 31, 1994, were between the ages
of 45 and 64 at their index statin dispensation,
and had remained alive for at least 4 months after
the index statin dispensation.
The observation period for each cohort member
included: 1) a medical antecedent period which ex-
tended from the individual’s date of first physician
or hospital visit following January 1, 1987, to the
index statin dispensation date; 2) a pharmaceuti-
cal antecedent period which extended from the in-
dividual’s date of first reimbursed prescription for
any medication following January 1, 1987, to the
index statin dispensation date; and 3) a follow-up
period which extended from the start of the indi-
vidual’s index dispensation to the date of death or
December 31, 1994.
 
Outcome Definitions
 
Two types of outcome variables were analyzed: a)
the frequency of renewal of the first (index) statin
dispensation (a dichotomous variable); and b) the
persistence on treatment with any statin, in days
from the date of the index dispensation (a contin-
uous variable). As represented diagrammatically
in part A of Fig. 1, we determined the frequency of
renewal of the first statin dispensation in two ways:
1) the proportion of those in each cohort who ever
renewed their initial (index) dispensation for a statin
by the end of the follow-up period (December 31,
1994), regardless of any gap between the end of the
first dispensation and the beginning of the renewal;
and 2) the proportion of those in each cohort who
were compliant renewers, defined as those who re-
newed their initial statin dispensation both within
the study period and within the permissible time pe-
riod (gap) between the prescribed end of the first
dispensation and the date of dispensation of the
next dispensation. The permissible gap following
the first dispensation was defined as a time period
equal to one half the duration of the index dispensa-
tion, or 7 days, whichever was longer. Patients who
switched from one brand of statin to another were
considered as continuing on statin therapy.
As depicted in part B of Figure 1, the persis-
tence on (duration of) statin treatment was de-
fined as the number of days from the date of the
start of the index dispensation (index date) to the
time of first failure to continue renewals of statin
with the permissible gap between dispensations.
As above, the permissible gap between the end
date of a given statin dispensation and the date of
renewal was defined as one half of the duration of
the given statin dispensation, or 7 days, whichever
was greater. The total duration of treatment in-
cluded the permissible gap following the final dis-
pensation completed within the study period; for
patients who remained on treatment at the end of
the study period the duration of treatment was cen-
sored at that date. It should be noted that this defi-
nition of persistence corresponds to the duration of
treatment during which adherence (proportion of
pills dispensed which would have been consumed if
taken as directed until the renewal date) remained
above 66%; patients were considered to have effec-
tively discontinued treatment at the point at which
adherence dropped to less than 66%.
 
Statistical Analysis
 
Predictors of persistence on statin treatment which
were suspected a priori from among the indicators
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available within the administrative databases of
RAMQ included: age at index date; gender; previ-
ous use (i.e., during the pharmaceutical antecedent
period) of other lipid modifying agents; previous
use of antihyperglycemic agents; the type of statin
initially prescribed (lovastatin, pravastatin, or sim-
vastatin); the timing (year) of statin therapy initia-
tion; the initial daily dose of statin (in mg per
day); the duration of the index statin dispensation;
a global index of chronic disease; and the pre-exis-
tence of cardiovascular disease. In addition, inter-
actions between gender and two other variables
(age and cardiovascular disease) were investigated.
The chronic disease score (CDS) was calculated
[10] by assigning scores (0–5) to classes of drugs
according to the severity of the disease for which
they were prescribed; the CDS was equal to the
sum of scores for drugs dispensed to the patients
during the index statin dispensation.
Pre-existing cardiovascular disease was indicated
by either of the following conditions: i) a diagno-
sis of ischemic heart disease (including acute myo-
Figure 1 Diagrammatic representation of study outcomes.
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cardial infarction, other acute and subacute forms
of ischemic heart disease, angina pectoris, and other
forms of chronic ischemic heart disease), heart
failure, atherosclerosis, or unspecified cardiovas-
cular disease (ICD-9 codes 410, 411, 412, 413, 428,
440, or 429.2); or ii) any dispensations for drugs
commonly prescribed for cardiovascular disease
including: nitrate derivatives (used for angina), or
digital and furosemide drugs used in combination
(for heart failure).
Survival functions describing persistence on sta-
tin treatment were computed using the product-limit
method [11]. Patients who remained on treatment at
the end of the follow-up period were censored at that
time, and contributed information to the survival
curve (as cumulative probability of survival on treat-
ment) only until that date.
For each of the two alternative definitions of re-
newal of the first dispensation and for each of the
suspected predictors, crude stratified analyses were
conducted by computing the frequency of renewal
within strata defined by categories of the predic-
tor. Crude and multivariate analyses to identify in-
dependent determinants of persistence on statin
treatment were conducted using Cox’s propor-
tional hazards model. Potential modifiers of the
assumed multiplicative relationship among model
covariates were also investigated. These evaluated
the potential for variable predictivity of age and
cardiovascular disease status by gender. The final
analysis included all variables observed to be sig-
nificant independent determinants of the persis-
tence on treatment. Statistical significance was de-
fined using a liberal alpha level of 0.10.
 
Results
 
Observation Periods
 
New users of statins included 983 social assistance
recipients whose pharmaceutical observation in-
cluded a total of 2,439,153 person-days (6678
person-years) and a median of 2874 days (8 years).
The antecedent period had a median duration of
1761 days (range 79, 2762) in terms of medical
services records, and a median duration of 1490
days (range 92, 2762) in respect to pharmaceutical
records. The median follow-up (from the date of
index dispensation) was 1032 days (range 156,
2191).
 
Baseline Characteristics
 
Characteristics of new users of statins are pro-
vided in Table 1, both for the entire cohort, and
according to compliant (time-limited) renewal (or
 
its complement, nonrenewal) of the index (first)
statin dispensation. Of the 983 new statin users
who comprised the cohort, 931 (95%) ever re-
newed their first dispensation of statin and 784
(80%) were compliant renewers who renewed
their first dispensation of statin within the defined
permissible period. The mean age at the date of
the index dispensation was 56 years. Thirty-four
percent of the cohort were males; the age distribu-
tion did not vary by gender. There was evidence of
pre-existing cardiovascular disease (CVD) in 41%
of the cohort, as indicated by either ICD-9 diag-
noses or medications indicative of CVD in their
antecedent medical or pharmaceutical records; 59%
of the cohort were thus presumed to have been re-
ceiving statin treatment as a primary prevention
strategy. Based on previous use of either oral anti-
hyperglycemic agents or insulin, 12% of the co-
hort were medicated diabetics. Twenty-eight per-
cent of the cohort had received dispensations for
other lipid modifying agents (fibrates, resins, or
nicotinic acid, in order of prevalence) in the phar-
maceutical antecedent period prior to the index dis-
pensation. The majority of index statin dispensa-
tions were for lovastatin (59%) with the remainder
being for pravastatin (23%) or simvastatin (18%).
The mean initial daily dose of statin was 18 mg.
As can be seen from Table 1, of the potential
determinants studied, only two factors, chronic
disease score and pre-existing CVD (as indicated
by previous diagnoses, or medications for, CVD),
were significant crude predictors of compliant re-
newal of the index statin dispensation. With re-
spect to the criteria for defining pre-existing CVD,
when analyzed separately, both previous CVD di-
agnoses (
 
P
 
 
 

 
 .019) and previous CVD medications
(
 
P
 
 
 

 
 .009) were significant predictors of compli-
ant renewal. The substantial agreement (83% over-
all) in patient classifications on CVD status by
these criteria are evident from Table 2. The kappa
statistic was equal to 0.61, indicating good agree-
ment between the two methods [11] of CVD clas-
sification.
 
Persistence on Statin Treatment
 
Figure 2 shows the survival curve depicting persis-
tence on statin treatment among the entire cohort
of new users. A steep drop (of 20%) in the num-
ber of patients remaining on treatment was ob-
served 45 days after the index date, which corre-
sponds to the end of the permissible renewal
interval following a typical 30-day dispensation.
Thereafter the curve continued to decline, though
at a decreasing rate. Persistence at one year was
 Long-term Statin Persistence Predictors
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only 33% (95% CI 
 

 
 30%, 36%). Just over a
third these patients (13%, 95% CI 
 

 
 10%, 16%)
persisted on treatment after 5 years. Median sur-
vival on statin treatment was 173 days (95% CI 
 

 
155, 204) or approximately six months.
 
Determinants of Persistence on Statin Treatment
 
Table 3 provides crude and adjusted rate ratios
and 95% CIs for the determinants of persistence
on statin which were observed to be important
within the cohort of new statin users based on
Cox proportional hazards regression. As is evident
from Table 3, for those factors that were signifi-
cant independent predictors of persistence in mul-
tivariate analyses, only marginal differences were
observed between crude and adjusted rate ratios.
Figure 3 graphically depicts the adjusted rate ra-
tios and 95% CIs. Figure 4 provides survival
curves depicting persistence on treatment for cate-
gories defined by the predictors.
In order of relative size, from those most strongly
favoring longer persistence to those most predictive
of earlier discontinuation (i.e., from smallest to
 
Table 1
 
Characteristics of new users of statin according to time-limited* renewal of the first dispensation
 
All new users
N 
 

 
 983
Non-renewers
N 
 

 
 199
Compliant renewers
N 
 

 
 784
Continuous Variables
Age at index dispensation (yrs) 56.2 
 

 
 5.2 55.5 
 

 
 5.2 56.3 
 

 
 5.1
Mean daily statin dose (mg) 18.4 
 

 
 5.9 18.9 
 

 
 6.9 18.3 
 

 
 5.7
Categorical Variables–no. of subjects (%)
Male gender 337 (34.3) 61 (30.6) 276 (35.2)
Pre-existing cardiovascular disease
 
†‡
 
405 (41.2) 66 (16.3) 339 (83.7)
Medicated diabetic
 
§
 
122 (12.4) 26 (13.1) 96 (12.2)
Chronic Disease Score
 
†
 

 
A
0 403 (41.0) 106 (53.3) 297 (37.9)
1–3 360 (36.6) 58 (29.2) 302 (38.5)
 

 
4 220 (22.4) 35 (17.6) 185 (23.6)
Previous Use of Other Antihyperlipidemic Agent
None 705 (71.7) 150 (75.4) 555 (70.8)
Fibrates 209 (21.3) 34 (17.1) 175 (22.3)
Resins 50  (5.1) 11  (5.5) 39  (5.0)
Nicotinic Acid 14  (1.4) 4  (2.0) 10  (1.3)
Other 5  (0.5) 0  (0.0) 5  (0.6)
Index Statin
Lovastastin 578 (58.8) 120 (60.3) 458 (58.4)
Pravastatin 231 (23.5) 45 (22.6) 186 (23.7)
Simvastatin 174 (17.7) 34 (17.1) 140 (17.9)
 
*Time-limited renewal refers to renewal of the first (index) statin dispensation within a permissible gap following the index dispensation, of duration equal to one
half of the intended duration of the index dispensation or 7 days, whichever was greater.
 
†
 
P
 
-value for chi-squared test 
 

 
.05.
 
‡
 
As indicated by previous diagnosis of cardiovascular disease (CVD) or previous use of CVD-related medications.
 
§
 
As indicated by previous use of either oral antihyperglycemic agents or insulin.
 

 
Classes of drugs were assigned scores (0-5) according to the severity of the disease for which they were prescribed; the chronic disease score was the sum of the
scores for other drugs dispensed to the patients during the index statin dispensation.
 
Table 2
 
Cardiovascular disease status as indicated by 
medications or diagnoses in the relevant antecedent period
 
Antecedent medication
for cardiovascular
disease
 
†
 
Antecendent diagnosis of 
cardiovascular disease*
Number of persons (%)
No Yes Total
No 578 (59) 90  (9) 668  (68)
Yes 77  (8) 238 (24) 315  (32)
Total 655 (67) 328 (33) 983 (100)
 
*As indicated by diagnoses of ischemic heart disease, including acute myocar-
dial infarction, other acute and subacute forms of ischemic heart disease,
angina pectoris, heart failure, atherosclerosis, or unspecified cardiovascular
disease (ICD-9 codes 410, 411, 412, 413, 428, or 440), in the medical anteced-
ent period; the median duration of the latter period was of 1761 days (range
79, 2762).
 
†
 
As indicated by dispensed medications for nitrate derivatives used for angina,
or digital and furosemide drugs used in combination for heart failure in the
pharmaceutical antecendent period; the median duration of the latter period
was 1490 days (range 92, 2762).
Figure 2 Persistence on statin treatment among new users
in a subsidized clinical cohort.
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largest adjusted RR point estimate in a model pre-
dicting failure to persist), independent predictors
of persistence included previous use of the lipid
modifying agent nicotinic acid, a relatively higher
index of chronic disease, the pre-existence of car-
diovascular disease, and type of statin initially dis-
pensed.
Although few (14 of 983) of the new statin us-
ers had received nicotinic acid in the pharmaceuti-
cal antecedent period prior to their initial statin
dispensation, these patients were (1–0.53) 47%
less likely to discontinue treatment, or (1/0.53) 1.9
(95% CI 
 

 
 0.98, 3.70) times more likely to persist
with treatment, at any given time postindex (con-
ditional on survival until that time) than those pa-
tients who had not (Table 3 and Figs 3 and 4a).
Those new statin users with greater levels of
chronic disease also showed higher rates of persis-
tence on statin treatment than those for whom the
statin drug was the only drug dispensed during the
index statin dispensation (Table 3 and Figs 3 and
4b). Individuals with a chronic disease score be-
tween 1 and 3 were 36% less likely to discontinue
treatment, or 1.4 (95% CI 
 

 
 1.15, 1.59) times
more likely to persist with treatment, than those
patients with a chronic disease score of 0. Cohort
members with a chronic disease score of more
than 4 were 40% less likely to discontinue treat-
ment, or 1.7 (95% CI 
 

 
 0.35, 2.08) times more
likely to persist with treatment, than those pa-
tients with a chronic disease score of 0.
New statin users who were presumed, on the basis
of previous CVD-related diagnoses or medications,
to have pre-existing CVD at the time of their first sta-
tin dispensation, were 39% less likely to discontinue
treatment, or 1.4 (95% CI 
 

 
 1.19, 1.67) times more
likely to persist with treatment than those patients
who did not (Table 3 and Figs 3 and 4c).
The initial type of statin dispensed also influ-
enced persistence on the drug class. Those new
 
Table 3
 
Crude and adjusted rate ratios from Cox Regression analyses predicting failure to persist on statin treatment
 
Crude Adjusted
Model covariate N Estimated Rate Ratio [95% CI]
 
P
 
 Value Estimated Rate Ratio [95% CI]
 
P
 
 Value
Previous nicotinic acid use
Yes 14 0.59 [0.31, 1.41] 0.1169 0.53 [0.27, 1.02] 0.0562
No (Reference) 969 1.00 1.00
Chronic disease score*
4–14 220 0.51 [0.42, 0.62] 0.0001 0.60 [0.48, 0.74] 0.0001
1–3 360 0.71 [0.61, 0.83] 0.0001 0.74 [0.63, 0.87] 0.0003
0 (Reference) 403 1.00 1.00
Pre-Existing Cardiovascular Disease
 
†
 
Yes 578 0.60 [0.51, 0.69] 0.0001 0.71 [0.60, 0.84] 0.0001
No (Reference) 405 1.00 1.00
Index Statin
Lovastatin 405 1.17 [1.01, 1.35] 0.0375 1.20 [1.04, 1.39] 0.0001
Pravastatin or Simvastatin (Reference) 578 1.00 1.00
 
*Classes of drugs were assigned scores (0–5) according to the severity of the disease for which they were prescribed; the chronic disease score was the sum of the
scores for other drugs dispensed to the patients during the index statin dispensation.
 
†
 
As indicated by previous diagnosis of cardiovascular disease (CVD) or previous use of CVD-related medications.
Figure 3 Determinants of persistence on statin treatment.
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statin users for whom lovastatin was the index
statin had a 20% higher rate of discontinuation
than those whose first statin dispensation was for
pravastatin or lovastatin (Table 3 and Figs 3 and
4d). The timing of statin therapy initiation (i.e.,
calendar year of the index dispensation) did not
account for this trend.
 
Discussion
 
A subsidized clinical cohort of new statin users
aged 45–64, whose first statin dispensation oc-
curred between January 1, 1987 and July 31, 1994,
demonstrated remarkably low persistence with
these lipid modifying agents. The proportions of
the cohort remaining on treatment at 1, 2, 3, 4, and
5 years following initiation, respectively, were 33%
(95% CI 
 

 
 27, 35), 24%, 17%, 14%, and 13%.
Only two other published studies to date have in-
vestigated persistence on lipid modifying agents
among new users using time-to-event (survival anal-
ysis) methods; both were limited in duration to one
year. Among 138 participating pharmacies in Syd-
ney, Australia, Simons [4] observed a 1-year rate
of persistence of 43% (95% CI 
 

 
 38, 48) on sim-
vastatin, and 44% (95% CI 
 

 
 37, 51) on pravas-
tatin (the only two statins studied) between 1994
and 1995. The latter 1-year rates are consistent with
those observed for these two agents in the present
study (36%, 95% CI 
 

 
 31, 41). In two Massa-
chusetts HMOs between 1988 and 1990, Andrade
et al. [3] observed a significantly higher 1-year per-
sistence probability of 85% (95% CI 
 

 
 71, 81)
for lovastatin (the only statin studied) compared
with that observed herein for this agent (31%,
95% CI 
 

 
 27, 35).
Substantial under-ascertainment of discontinu-
ation is likely in Andrade’s study in which discon-
tinuation was identified by one of three condi-
tions: a switch to another type of lipid modifying
agent; a 6-month gap between the last refill and
the end of the study period or plan termination
(regardless of the duration of the last refill); or
omitted or inactive lipid modifying therapies flagged
in clinical encounter files. In the present study, dis-
continuation was presumed on the basis of the
failure of the patient to renew a completed dispen-
sation of any statin agent within a permissible gap
whose length was calibrated to the duration of the
previous dispensation (being the maximum of seven
days, or half of the intended duration of the previ-
ous prescription). The use of an arbitrary fixed
gap by both Andrade et al. [3] and Simons et al.
[4] introduced a degree of systematic error to the
ascertainment of discontinuation that is consistent
with the observed degree of interstudy discrepancy
in estimated 1-year persistence rates. Since the me-
dian and mean pharmaceutical dispensation dura-
Figure 4 Persistence on statin treatment by significant predictors.
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tion (at least in Québec) is 30 days [9], such error
would have been much greater in the case of An-
drade’s study, which used a 6-month gap, than
was the case in the study by Simons, in which the
effective lag period varied between four and eight
weeks.
In addition to the type of statin prescribed at
the index dispensation, we identified three other
independent predictors of persistence on statin
treatment: previous use of nicotinic acid; comor-
bidity as indicated by the chronic disease score;
and pre-existing cardiovascular disease (as indicated
by prior medical diagnoses and CVD-related medi-
cation dispensations). After accounting for these fac-
tors, age at index date, gender, the timing (year) of
statin therapy initiation, the initial daily dose of
statin (in mg per day), duration of the index statin
dispensation, and interactions between gender and
two other variables (age and cardiovascular dis-
ease) were not predictive of statin persistence. It
should be noted that conversions from one statin to
another could not have affected our results, since a
patient switching from one brand to another was
considered as persisting on statin therapy.
The higher persistence observed among previ-
ous nicotinic acid users may be a selective phe-
nomenon. The proportion of patients who never
filled a second prescription or switched to another
class of antilipid agent was observed by Avorn et al.
[6] to be greater for nicotinic acid (89.1%) com-
pared with cholestyramine, gemfibrozil, probucol
or lovastatin (range 20–45%). The minority of pa-
tients who successfully persist with this relatively
unfavourable agent are therefore more likely to per-
sist with statin treatment when it is prescribed.
Our observation that persistence is better among
patients with pre-existing cardiovascular disease
confirmed similar findings by Simons [4] and Avorn
et al. [6] In the latter study, Avorn et al. observed
that the proportion of days covered by a dispensa-
tion (a measure which we term adherence) over one
year was associated with coronary artery disease,
hypertension, and diabetes. As did Avorn et al. we
observed an association between persistence on
statins and comorbidity (as indicated by medica-
tions received for other conditions including hyper-
tension and diabetes). The importance of comorbid-
ity may simply reflect behavioural habit; patients
who are already consuming pharmaceuticals on a
regular basis more readily persist with the addition
of another pill to their existing drug-taking regi-
men than do patients who must establish a drug-
taking regimen, particularly in the absence of a dis-
ease diagnosis or symptoms.
Andrade et al’s [3] finding of a higher rate of
discontinuation among women was observed only
in our crude Cox regression analysis, but gender
appeared to be a confounding factor associated
with pre-existing CVD. Andrade et al. evidently
did not investigate in multivariate analyses this or
other possible factors that accounted for crude
gender differences. The survival analyses by An-
drade stratified only by subjectively inferred rea-
sons for discontinuation (based on review of med-
ical charts) categorized as either adverse effects,
perceived drug ineffectiveness and noncompliance.
Consistent with our negative findings with respect
to gender, both Simons [4] and Avorn et al. [6]
ruled out gender as an independent determinant of
persistence on lipid modifying agents.
Advancing age is another potentially confound-
ing factor that has been reported in other studies
[3,4] to be predictive of persistence. As noted by
Avorn et al. [6] old age is not a risk factor per se for
reduced persistence, but rather is associated with
chronic disease, which we accounted for in our
analyses. We also controlled for confounding by
age by restricting our cohort to those patients who
were 45–64 years of age at the index dispensation.
The particular strengths of the present investiga-
tion include: a relatively long-term follow-up (up to
6 years postindex with a median of 3 years); a clear
and consistent definition of persistence (equivalent
to a minimum 66% adherence to any single dispen-
sation) with a permissible gap calibrated to the du-
ration of the previous dispensation; the investiga-
tion of a large set of objectively defined potential
determinants of treatment persistence; control of
potential confounders such as gender (through mul-
tivariate analysis) and age (through cohort restric-
tion); and the investigation of potential modifying
factors (through interaction terms defined a priori).
Previous analyses by our pharmacoepidemiol-
ogy unit (for example, Desgagné and LeLorier [12])
have routinely used the cut-off value of 66%, per-
mitting us to make consistent comparisons between
drugs and classes of drugs. While this value (of
66%) may seem overly precise, it simply results
from (admittedly arbitrarily) allowing a permissible
time equal to one and one half times the intended
duration of a prescription (or 7 days, whichever is
greater) for a person to renew a dispensation. In
these natural units, allowing a gap of one half the
intended dispensation duration seemed reason-
able. Concerned, however, that the above might be
viewed as unduly strict, we undertook a sensitivity
analysis which relaxed this definition such that a
period double that intended by the prescriber was
 Long-term Statin Persistence Predictors
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allowed to consider a patient compliant without
substantive impact on the analytic results. Al-
though median persistence was increased (from
170 to 244 days, or 0.47–0.67 years), it remained
low, and the same set of predictors were identified
as important determinants of persistence on sta-
tins.
This study of new statin users is subject to a
number of limitations, however, the most promi-
nent of which are discussed below. The first of
limitations concerns the source of the data; we
were limited herein to information routinely col-
lected by the provincial health plan’s administra-
tive databases. The available data indicates only
drugs dispensed, rather than drugs consumed. We
could therefore infer persistence only from the fact
of continued (renewed) dispensations. We may
thus have overestimated persistence. Also unavail-
able to us was qualitative information such as one
might ascertain from patient interview, e.g., sub-
jective reasons for discontinuation of the drug
such as a belief that the treatment is ineffective, or
that the adverse effects were not balanced by en-
hanced feelings of wellness.
Another limitation related to the source of data
is the fact that hospitals and other in-patient insti-
tutions do not submit drug claims data to RAMQ,
and hence such prescription data is missing from
the database. Some cohort members could have
been admitted to institutions for a sufficient dura-
tion during the follow-up period to have been pre-
sumed discontinued from therapy. This would have
led to an underestimate of persistence. Similar un-
detected losses could have occurred if members
became employed during the period of follow-up.
Unfortunately, no data are available with regard
to this possibility.
The results of this study of a social assisted clin-
ical population may be of limited generalizability
to other socio-economic classes, regardless of sub-
sidization of drug costs. According to Avorn et al.
[6] persistence on lipid modifying agents over one
year was related to socio-economic class, but not
to drug costs among subsidized patients; Simons
[4] also observed medication costs to be unrelated to
persistence. The present study may therefore some-
what under-estimate persistence in a broader clini-
cal population.
This analysis has revealed low levels of persis-
tence on statins among social assistance recipients
aged 45–64 in the province of Québec. To the ex-
tent that these rates are generalizable to clinical
populations at large, the potential impacts both
clinical and economic, of such low persistence, are
 
alarming. Large long-term (5 years follow-up) clini-
cal trials have demonstrated the efficacy of statins
for both primary and secondary prevention of CVD
in men of similar age with hyperlidaemia; in terms
of the most conservative outcome, all-cause mor-
tality, the WOSCOPS trial of pravastatin in 6595
subjects without CVD resulted in a 22% (95%
CI 
 

 
 0, 40; 
 
P
 
 
 

 
 .051) greater survival probability
among those treated compared to those on pla-
cebo [13]; the 4S trial of simvastatin in 4444 sub-
jects with CVD [14] resulted in a 30% (95% CI 
 

 
14, 42; 
 
P
 
 
 

 
 .0003) reduction in relative risk. In
both trials, the statins were well tolerated, with
similar frequencies of adverse events and study
withdrawals in the treated and placebo groups.
Because statins require sustained use for mainte-
nance of their therapeutic action, however, the pre-
mature loss of patients from long-term treatment
in general clinical practice constitutes a waste of
health care dollars spent on medications that may
ultimately benefit a fraction of those to whom
they are dispensed.
Efforts must be made to educate patients of the
importance to drug effectiveness of persistence;
physicians considering prescribing statins for pri-
mary prevention may be justified in reserving their
prescription to those patients who, once informed,
express an intention to persist with treatment once
it is prescribed.
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